INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 94 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 34.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $691,000 | +92.5% | 213,942 | -19.4% | 0.00% | – |
Q4 2016 | $359,000 | -8.2% | 265,558 | +5.9% | 0.00% | – |
Q3 2016 | $391,000 | +64.3% | 250,879 | +40.4% | 0.00% | – |
Q2 2016 | $238,000 | -71.0% | 178,736 | +14.7% | 0.00% | -100.0% |
Q1 2016 | $821,000 | -57.6% | 155,864 | -36.8% | 0.00% | 0.0% |
Q4 2015 | $1,935,000 | -36.2% | 246,514 | -31.4% | 0.00% | -50.0% |
Q3 2015 | $3,035,000 | -25.6% | 359,204 | -3.6% | 0.00% | -33.3% |
Q2 2015 | $4,079,000 | -17.3% | 372,536 | +5.6% | 0.00% | 0.0% |
Q1 2015 | $4,930,000 | +18.9% | 352,633 | +43.6% | 0.00% | 0.0% |
Q4 2014 | $4,147,000 | +72.3% | 245,557 | +36.9% | 0.00% | +50.0% |
Q3 2014 | $2,407,000 | +2.4% | 179,333 | -2.8% | 0.00% | 0.0% |
Q2 2014 | $2,351,000 | +6.6% | 184,565 | -0.5% | 0.00% | 0.0% |
Q1 2014 | $2,206,000 | -14.9% | 185,558 | -1.2% | 0.00% | 0.0% |
Q4 2013 | $2,593,000 | -22.5% | 187,798 | -2.0% | 0.00% | -33.3% |
Q3 2013 | $3,346,000 | +5.7% | 191,726 | -1.6% | 0.00% | 0.0% |
Q2 2013 | $3,167,000 | – | 194,863 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |